Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Hur effektivt är alemtuzumab respektive daclizumab vid behandling av multipel skleros?
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.
2017 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesisAlternative title
How effective is alemtuzumab and daclizumab respectively as a treatment for multiple sclerosis? (English)
Abstract [en]

Background: Multiple sclerosis (MS) is an autoimmune disease which attacks the central nervous systems (CNS) white substance. The damages cause MS-plaques which lead to disability in the CNS. There are currently around 20,000 people in Sweden who live with the diagnosis and every year another 1,000 people develop MS. It is twice as common for women to suffer from MS in comparison with men. Objective: The purpose of the study was to investigate the efficacy and safety of the alemtuzumab and daclizumab infusion drugs. Methods: This work is a literature study based on 6 scientific articles. Results: Based on at least one of the studied parameters, which are improvement in Expanded Disability Status Scale (EDSS), annual relapse rate and sustained accumulation of disability (IFS), showed that all four studies on alemtuzumab provided a higher therapeutic effect than IFN-β-1a. The two studies on daclizumab showed in one article in comparison with placebo a better treatment effect. The article comparing daclizumab with IFN-β-1a did not show major differences between the preparations but a reduced annual relapse rate was observed. Conclusion: The studies showed that both alemtuzumab and daclizumab yield better effect than IFN-β-1a and placebo. Treatment with alemtuzumab gave slightly better results in persistent worsening of the disease (IFS) compared with daclizumab, IFN-β- 1a and placebo. Patients who were treated with alemtuzumab had worse adverse events in comparison to the group of patients who were treated with IFN-β-1a. This shows that the safety of treatment with alemtuzumab was lower in comparison to treatment with IFN-β-1a. Most fatal outcomes were found during treatment with alemtuzumab. These aspects makes one consider whether alemtuzumab may or may not be the best treatment option. Also daclizumab had some serious side effects, but those did not occur as much as with alemtuzumab treatment. IFN-β-1a has been a safer drug to use as compared to alemtuzumab and dalclizumab. On the other hand, the mechanism of action differs between the three drugs, which means that these can be tailored more individually to MS-affected patients and a more individual-based drug treatment may be possible.

Place, publisher, year, edition, pages
2017. , 53 p.
Keyword [en]
multiple sclerosis, alemtuzumab, daclizumab, interferon beta-1a
Keyword [sv]
multipel skleros, alemtuzumab, daclizumab, interferon beta-1a
National Category
Medical and Health Sciences Natural Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-64471OAI: oai:DiVA.org:lnu-64471DiVA: diva2:1102633
Subject / course
Biomedical Sciences
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Supervisors
Examiners
Available from: 2017-05-31 Created: 2017-05-29 Last updated: 2017-05-31Bibliographically approved

Open Access in DiVA

NereidaLimani-MultipelSkleros-Cuppsats-Linneuniversitetet(973 kB)12 downloads
File information
File name FULLTEXT01.pdfFile size 973 kBChecksum SHA-512
3a606dffaf37cfff02ca341381e945d8055a13ea969b55ff75a959684658eb0ed86ea8ced032d6de9b4d4eb5a167015459b0d7354a2d0847ce85a32120eca536
Type fulltextMimetype application/pdf

By organisation
Department of Chemistry and Biomedical Sciences
Medical and Health SciencesNatural Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 12 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 30 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf